Zobrazeno 1 - 10
of 713
pro vyhledávání: '"Edward M. Sellers"'
Autor:
Bohn, Michael J.
Publikováno v:
The Quarterly Review of Biology, 1991 Jun 01. 66(2), 231-232.
Externí odkaz:
https://www.jstor.org/stable/2830301
Autor:
Guy A. Higgins, Nicole K. Carroll, Matt Brown, Cam MacMillan, Leo B. Silenieks, Sandy Thevarkunnel, Julia Izhakova, Lilia Magomedova, Ines DeLannoy, Edward M. Sellers
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Long term benefits following short-term administration of high psychedelic doses of serotonergic and dissociative hallucinogens, typified by psilocybin and ketamine respectively, support their potential as treatments for psychiatric conditions such a
Externí odkaz:
https://doaj.org/article/60248d7199844455b8f88ef139c114c6
Autor:
Michael J. Bohn
Publikováno v:
The Quarterly Review of Biology. 66:231-232
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cca4231f001d09c2200eae379ee4d313
https://doi.org/10.1086/417215
https://doi.org/10.1086/417215
Autor:
Fink, Max
Publikováno v:
The Quarterly Review of Biology, 1985 Dec 01. 60(4), 552-552.
Externí odkaz:
https://www.jstor.org/stable/2829938
Autor:
Edward M. Sellers, Myroslava K. Romach
Publikováno v:
Neuropharmacology. 227:109426
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d11a70ed080136b77779a04fcc6c7f42
https://doi.org/10.1016/j.neuropharm.2023.109426
https://doi.org/10.1016/j.neuropharm.2023.109426
Autor:
Catherine Mills, Nancy Chen, Beatrice Setnik, Cynthia Bartlett, Naama Levy-Cooperman, Sian Ratcliffe, Kerri A. Schoedel, Megan J. Shram, Edward M. Sellers
Publikováno v:
Journal of Clinical Psychopharmacology. 40:568-578
Background Human abuse potential studies include multiple measures to assess the subjective effects of central nervous system-active drugs. In this retrospective analysis, measurement properties of commonly used measures were assessed, and factor ana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05181feca4c3f624ce5c3252791eb2ae
https://doi.org/10.1097/jcp.0000000000001302
https://doi.org/10.1097/jcp.0000000000001302
Autor:
Edward M. Sellers, Li Shen Loo, Erin G Doty, Darren Wilbraham, Paul Berg, Max Tsai, Emily Liffick
Publikováno v:
Journal of Clinical Pharmacology
Lasmiditan is a centrally penetrant, highly selective 5‐hydroxytryptamine (serotonin) receptor 1F (5HT1F) agonist under development as a novel therapy for acute treatment of migraine. A phase 1 randomized, placebo‐ and positive‐controlled cross
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8760e4485c07f9efd1185d9fa84470ea
http://europepmc.org/articles/PMC7078915
http://europepmc.org/articles/PMC7078915
Autor:
Guy A, Higgins, Edward M, Sellers
Publikováno v:
Progress in brain research. 259
Nicotine use and dependence, typically achieved through cigarette smoking, but increasingly through vape products, is the leading cause of preventable death today. Despite a recognition that many current smokers would like to quit, the success rate a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f069ea9b3f67f3984e03b8267acc77ef
https://pubmed.ncbi.nlm.nih.gov/33541678
https://pubmed.ncbi.nlm.nih.gov/33541678
Autor:
Edward M. Sellers, Guy A. Higgins
Publikováno v:
Progress in Brain Research ISBN: 9780128245675
Nicotine use and dependence, typically achieved through cigarette smoking, but increasingly through vape products, is the leading cause of preventable death today. Despite a recognition that many current smokers would like to quit, the success rate a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::167d9ee626f7790b4fc956777c2399a8
https://doi.org/10.1016/bs.pbr.2021.01.007
https://doi.org/10.1016/bs.pbr.2021.01.007
Autor:
Kerri A. Schoedel, Tilden Etges, Beatrice Setnik, Edward M. Sellers, Isabella Szeto, Catherine Mills, Naama Levy-Cooperman, Kenneth W. Sommerville
Publikováno v:
Epilepsy & Behavior. 88:162-171
Rationale Treatment with a highly purified oral solution of cannabidiol (CBD), derived from the plant Cannabis sativa L., demonstrated some evidence of central nervous system (CNS)-related adverse events in patients enrolled in phase 3 trials for tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d525e52d88da2bf3cb143416a3c0a9dc
https://doi.org/10.1016/j.yebeh.2018.07.027
https://doi.org/10.1016/j.yebeh.2018.07.027